Small Molecule API Market by Deployment and Geography - Forecast and Analysis 2022-2026

  • Published: Jan 2022
  • Pages: 120
  • SKU: IRTNTR71969
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The small molecule API market share is expected to increase by USD 71.10 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 7.89%.

This small molecule API market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers small molecule API market segmentation by deployment (captive APIs and contract APIs) and geography (North America, Asia, Europe, and ROW). The small molecule API market report also offers information on several market vendors, including Aurobindo Pharma Ltd., Cambrex Corp., Cipla Inc., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc. among others.

What will the Small Molecule API Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Small Molecule API Market Size for the Forecast Period and Other Important Statistics

 

Small Molecule API Market: Key Drivers and Challenges

The evolving small-molecule API manufacturing scenario in developing countries is notably driving the small molecule API market growth, although factors such as high investment cost and concern of huge financial loss may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the small molecule API industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Small Molecule API Market Driver

India and China are rapidly evolving as viable sources for key intermediates and bulk actives. Considering the presence of developed infrastructure and growing economic development, India and China have started producing high-quality small-molecule APIs and drug intermediates for regulated markets. Also, innovators have started focusing on these countries for outsourcing late-stage intermediates, and a few global manufacturers have formed joint ventures with local small-molecule API manufacturers. Furthermore, it was observed that the innovators are increasingly partnering with local API manufacturers for high-quality bulk manufacturing activities, particularly with those in developing countries, owing to low development and production costs. On average, the manufacturing cost of APIs for generic oral solids, such as tablets and capsules, accounts for approximately 40%-50% of the production cost. In a highly competitive market, where the ability to offer a low price is vital, generic drug manufacturers seek competitive advantages by outsourcing bulk drug manufacturing activities to reliable small-molecule API manufacturers in developing countries that can deliver small-molecule APIs at a low cost. This is expected to drive the growth of the market during the forecast period. 

Key Small Molecule API Market Challenge

Meeting small-molecule API GMP is mandatory wherever the small-molecule API production or consumption is expected to comply with the ICH guidelines. Non-adherence to these guidelines might restrict the entry of small-molecule API in the regulated markets, thereby causing significant loss to small-molecule API manufacturers. An increase in the general WLs issued by the US FDA to small-molecule API manufacturers has led these manufacturers to improve their API manufacturing facilities and adherence to the GMP protocol. This, in turn, requires an increased investment of time, labor, and continuous availability of funds to upgrade the manufacturing facilities as per the validated GMP protocol, thus making it difficult to achieve the economies of scale by small-molecule API manufacturers under such a stringent regulatory framework. Failure to adhere to the validated GMP protocol may restrict the entry of bulk actives into the regulated market, thus exposing API manufacturers to huge financial losses. This discourages manufacturers from venturing into the API industry, thereby limiting the growth prospects of the small molecule API market.

This small molecule API market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Who are the Major Small Molecule API Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Aurobindo Pharma Ltd.
  • Cambrex Corp.
  • Cipla Inc.
  • Dr. Reddys Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

 

This statistical study of the small molecule API market encompasses successful business strategies deployed by the key vendors. The small molecule API market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The small molecule API market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for Small Molecule API Market?

For more insights on the market share of various regions Request for a FREE sample now!

42% of the market’s growth will originate from North America during the forecast period. The US is a key market for small molecule API in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia.

The rising geriatric population in the US and the growing prevalence of chronic diseases will facilitate the small molecule API market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Deployment Segments in the Small Molecule API Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The small molecule API market share growth by the captive APIs segment will be significant during the forecast period. This report provides an accurate prediction of the contribution of all the segments to the growth of the small molecule API market size and actionable market insights on post COVID-19 impact on each segment.

 

Small Molecule API Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 7.89%

Market growth 2022-2026

$ 71.10 billion

Market structure

Fragmented

YoY growth (%)

7.20

Regional analysis

North America, Asia, Europe, and ROW

Performing market contribution

North America at 42%

Key consumer countries

US, China, Japan, India, and Germany

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Aurobindo Pharma Ltd., Cambrex Corp., Cipla Inc., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Small Molecule API Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive small molecule API market growth during the next five years
  • Precise estimation of the small molecule API market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the small molecule API industry across North America, Asia, Europe, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of small molecule API market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

Executive Summary

    Market Landscape

    • Market ecosystem
    • Value chain analysis

    Market Sizing

    • Market definition
    • Market segment analysis
    • Market size 2021
    • Market outlook: Forecast for 2021 - 2026

    Five Forces Analysis

    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition

    Market Segmentation by Deployment

    • Market segments
    • Comparison by Deployment
    • Captive APIs - Market size and forecast 2021-2026
    • Contract APIs - Market size and forecast 2021-2026
    • Market opportunity by Deployment

    Geographic Landscape

    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2021-2026
    • Asia - Market size and forecast 2021-2026
    • Europe - Market size and forecast 2021-2026
    • ROW - Market size and forecast 2021-2026
    • Key leading countries
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Market trends

    Vendor Landscape

    • Vendor landscape
    • Landscape disruption

    Vendor Analysis

    • Vendors covered
    • Market positioning of vendors
    • Aurobindo Pharma Ltd.
    • Cambrex Corp.
    • Cipla Inc.
    • Dr. Reddys Laboratories Ltd.
    • GlaxoSmithKline Plc
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.

    Appendix

    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

    Research Framework

    Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

    TechnavioINFORMATION SOURCES

    Primary sources

    • Manufacturers and suppliers
    • Channel partners
    • Industry experts
    • Strategic decision makers

    Secondary sources

    • Industry journals and periodicals
    • Government data
    • Financial reports of key industry players
    • Historical data
    • Press releases
    Technavio

    TechnavioDATA ANALYSIS

    Data Synthesis

    • Collation of data
    • Estimation of key figures
    • Analysis of derived insights

    Data Validation

    • Triangulation with data models
    • Reference against proprietary databases
    • Corroboration with industry experts
    Technavio

    TechnavioREPORT WRITING

    Qualitative

    • Market drivers
    • Market challenges
    • Market trends
    • Five forces analysis

    Quantitative

    • Market size and forecast
    • Market segmentation
    • Geographical insights
    • Competitive landscape
    Interested in this report?
    Get your FREE sample now!
    The small molecule api market growth will increase by $71.10 billion during 2021-2026.
    The small molecule api market is expected to grow at a CAGR of 7.89% during 2021-2026.
    Technavio has segmented the small molecule api market by deployment (Captive APIs and Contract APIs) and geographic (North America, Asia, Europe, and ROW).
    Aurobindo Pharma Ltd., Cambrex Corp., Cipla Inc., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc. are a few of the key vendors in the small molecule api market.
    North America will register the highest growth rate of 42.29% among the other regions. Therefore, the small molecule api market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
    The key factors driving the small molecule api market growth are:
    • Evolving small-molecule API manufacturing scenario in developing countries
    The small molecule api market vendors should focus on grabbing business opportunities from the captive apis segment as it accounted for the largest market share in the base year.
    Safe and Secure SSL Encrypted
    Technavio

    Single User:

    2500 USD

    Technavio Get the report (PDF) sent to your email within minutes.

    Subscribe & Save

    Get lifetime access to our
    Technavio Insights

    Want to customize this report?

    This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

    We offer $1000 worth of FREE customization at the time of purchase
    Technavio
    Enquire Before Buying
    1. Home
    2. Health Care
    3. Published Report
    17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>